Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

2024-04-02

临床2期免疫疗法临床3期

SHELTON, Conn., April 2, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XIV 2024. The conference is being held on April 8 - 9, 2024 at the Sofitel Hotel in New York City.

https://ldinv14.sequireevents.com/

Mr. Bender will be available for one-on-one meetings with registered investors of the conference. To schedule a one-on-one meeting please contact Dean Summers at LD Micro ([email protected]) or Justin Kulik at [email protected].

About Intensity Therapeutics

Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry to turn "cold" tumors "hot" by enabling its aqueous cytotoxic-containing drug product, INT230-6, to disperse throughout and saturate the dense, high-fat pressurized environment of the tumor following direct intratumoral injection. As a result of the tumor saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill the cancer and elicit an adaptive immune response within days of injection, representing a novel approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases. INT230-6 has completed enrollment of over 200 patients in a Phase 1/2 dose escalation trial (NCT03058289) and Phase 2 randomized control clinical trial in breast cancer (the INVINCIBLE-2 study) (NCT04781725). The Company is initiating a Phase 3 trial in soft tissue sarcoma (the INVINCIBLE3 study) (NCT06263231), testing INT230-6 as second or third line monotherapy compared to the standard of care with overall survival as an endpoint. The Company is also planning a Phase 2/3 program in presurgical triple negative breast cancer testing INT230-6 in combination with standard of care compared to standard of care alone. For more information about the Company, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the expected future plans, development activities, projected milestones, business activities or results. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include: the risk that the anticipated milestones may be delayed or not occur or be changed, as well as other risks described in the section entitled "Risk Factors" in the Company's SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor Relations Contact:

Justin Kulik

[email protected]

(585) 230 6401

Media Contact:

Jules Abraham

CORE IR

[email protected]

SOURCE Intensity Therapeutics Inc.